Fabtech Technologies Limited has received an international contract from a veterinary manufacturing company based in North Africa. The project involves the construction of a facility that will follow EU Good Manufacturing Practice (GMP) standards.
The plant is expected to handle exports to the European Union and nearby African countries. The client’s name has not been shared due to confidentiality obligations.
The contract is valued between ₹49 crore and ₹52 crore, excluding taxes and levies. The scope covers the setup of a new veterinary formulations facility with full design and execution responsibility.
The order terms are based on standard industry conditions, as mentioned in the company’s disclosure.
The order was received on November 3, 2025. Fabtech Technologies has stated that the project is expected to be completed by the first quarter of 2027. The company will handle the project from initial setup to completion within this period.
The order has been awarded by an overseas entity in the North African region. The facility, once operational, will hold EU GMP certification, allowing it to export veterinary products to European and African markets.
This certification ensures that the production meets regulated standards required for export.
As per the filing, there is no connection between the awarding entity and Fabtech’s promoter group or subsidiaries.
The order does not come under related-party transactions. The company has not disclosed any additional details about the client or contract terms due to confidentiality agreements.
Read More: IFSCA Hits $100 Billion in Banking Assets at GIFT City!
As of November 6, 2025, 10:18 AM, Fabtech Technologies share price was trading at ₹234.66, a 1.29% decline from the previous close.
The project, valued at up to ₹52 crore, is targeted for completion by early 2027 and involves building a veterinary formulations facility for exports from North Africa.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Nov 6, 2025, 11:27 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
